

Michael Gold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4507114/publications.pdf>

Version: 2024-02-01

26
papers

1,330
citations

623734

14
h-index

454955

30
g-index

41
all docs

41
docs citations

41
times ranked

2093
citing authors

#	ARTICLE	IF	CITATIONS
1	Current directions in tau research: Highlights from Tau 2020. <i>Alzheimer's and Dementia</i> , 2022, 18, 988-1007.	0.8	42
2	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 511-524.	2.6	5
3	Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 83-100.	2.6	56
4	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 182-192.	10.2	74
5	Elezanumab, a human anti-RGMA monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates. <i>Neurobiology of Disease</i> , 2021, 155, 105385.	4.4	14
6	Building clinically relevant outcomes across the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12181.	3.7	16
7	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. <i>Alzheimer's and Dementia</i> , 2020, 16, 131-143.	0.8	45
8	Hippocampal Neuroimaging-Informed Clinical Trial Enrichment Tool for Amnesic Mild Cognitive Impairment Using Open Data. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 903-914.	4.7	2
9	New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia. <i>Alzheimer's and Dementia</i> , 2018, 14, 703-706.	0.8	6
10	Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 234-242.	3.7	104
11	Lacosamide and concomitant use of antiepileptic and other medications in a US population - A retrospective cohort study. <i>Epilepsy and Behavior</i> , 2017, 72, 51-57.	1.7	4
12	Potential roles of digital technologies in clinical trials. <i>Alzheimer's and Dementia</i> , 2017, 13, 1075-1076.	0.8	6
13	Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 402-409.	3.7	69
14	P402: A Phase 3, 26-Week, Double-Blind, Randomized, Placebo-Controlled Study of AC1204 in Mild-to-Moderate Alzheimer's Disease: Study Design and Progress. <i>Alzheimer's and Dementia</i> , 2016, 12, P1014.	0.8	0
15	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 41-48.	2.2	33
16	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 676-685.	10.2	245
17	Improving Alzheimer's disease phase II clinical trials. , 2013, 9, 39-49.		27
18	The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	0.8	48

#	ARTICLE	IF	CITATIONS
19	Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. <i>Alzheimer's and Dementia</i> , 2013, 9, 176-188.	0.8	58
20	Modeling Alzheimer's disease progression using the disease system analysis approach. <i>Alzheimer's and Dementia</i> , 2012, 8, 39-50.	0.8	29
21	Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 131-146.	1.5	299
22	Double-Blind, Controlled Phase II Study of a 5-HT ₆ Receptor Antagonist, SB-742457, in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2010, 999, 1-12.	1.4	2
23	Alzheimer's disease is not associated with the hypertension genetic risk factors PLA2 or G protein β_3 , either independently or interactively with apolipoprotein e. <i>American Journal of Medical Genetics Part A</i> , 1999, 88, 465-468.	2.4	4
24	A 67-Year-Old Woman with Polymyalgia Rheumatica and Left Hemispatial Neglect. <i>Journal of Neuroimaging</i> , 1998, 8, 222-227.	2.0	1
25	A 66-Year-Old Woman with a Rapidly Progressing Dementia and Basal Ganglia Involvement. <i>Journal of Neuroimaging</i> , 1997, 7, 171-175.	2.0	9
26	Hearing Loss in a Memory Disorders Clinic. <i>Archives of Neurology</i> , 1996, 53, 922.	4.5	70